Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

Psychiatric Times spoke with Altha Stewart, MD, to discuss Black history in mental health care and strides the psychiatric community is making to ensure a more inclusive future.

Let's reflect on managed care as we celebrate the 40th anniversary of Psychiatric Times.

Mena Mirhom, MD, FAPA, introduces his new column focused on mastering media as a mental health clinician.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

"She walks in beauty, like the night, Of cloudless climes and starry skies; And all that’s best of dark and bright, Meet in her aspect and her eyes..."

Today, let’s be loving to the environment and each other.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how optimizing SSRI dosage, potentially augmenting with another medication class, and intensifying psychosocial support helps address breakthrough PPD symptoms in mothers with partial response to current SSRI treatment.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Unlocking peak performance starts with the mind—Wilsa Charles Malveaux, MD, MA, FAPA, breaks the stigma around mental health in sports.

Check out these 7 insights and perspectives on recognizing and treating PTSD.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

"It is the winter of chest pain and snow, all the drunks smashed through the ER doors..."

Is physician burnout slowing down?

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

Is love a dirty word in psychiatry?

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

By addressing grief, loss, and sport-specific treatment needs, she helps athletes recover mentally and return to peak performance.

How best can a clinician advise their patients during hardships?

Test-drive this 7-fold model in your own practice.

The therapeutic nature of crying, in all professions…